Figure 1. The overall study timeline in ILIT after SCIT- 10 000 and ILIT de novo- 3000 . SCIT= Subcutaneous Immunotherapy. SPT= Skin Prick Test. NPT= Nasal Provocation Test. CSMS= Combined Symptoms and Medication Scores. RQLQ= Rhinitis Quality of Life Questionnaire.
Figure 2. The mean daily CSMS and the pollen levels before and after treatment at the different study sites. A . The baseline season of ILIT after SCIT-10 000. B . The season after treatment in ILIT after SCIT- 10 000. C . The baseline season of ILIT de novo- 3000. D. The season after treatment in ILIT de novo- 3000.
Figure 3. The symptoms and medication diary.A . The CSMS in ILIT after SCIT- 10 000 was reduced in the active (p= 0.005) but not in the placebo group. The SS did not improve significantly after treatment. The MS improved in the active group (p=0.003) but not in the placebo group. B. In ILIT de novo- 3000 the CSMS, SS and MS improved in both the active and placebo group after treatment. * p< 0.05, **p<0.01, n.s.=not significant.
Figure 4. Serologic changes after ILIT. Timothy specific IgG4 levels in A. ILIT after SCIT- 10 000 and B. ILIT de novo- 3000. Timothy specific IgE levels in C. ILIT after SCIT- 10 000 and D. ILIT de novo- 3000. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n.s.= not significant.
Figure 5. The expression of CD80, CD86 and CD141 increases on lymph node DCs after active ILIT. Fig. A, B and C . The level of expression on DCs in lymph nodes. Fig. D, E and F. The level of expression on DCs in blood. Fig A-F . The scatter plot represents the median levels of expression revealed by flow cytometry. In the group before treatment both placebo and active ILIT are included. *P<0.05, n.s.= not significant. Horizontal lines represent the mean value and SD.